The upgrade in rating from UBS analyst Eliana Merle indicates a positive outlook for Moderna's stock, as she believes the potential for mRNA vaccines in diseases beyond Covid is underappreciated. This could lead to increased investor interest and a short-term positive impact on the stock price.